BIBLIOS

  Ciências References Management System

Visitor Mode (Login)
Need help?


Back

Publication details

Document type
Book chapters


Title
Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events

Participants in the publication
Ana M. Matos (Author)
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA
CQE
Patrícia Calado (Author)
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA
William Washburn (Author)
Amélia P. Rauter (Author)
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA

Summary
Diabetes mellitus comprises serious metabolic disorders currently affecting almost 500 million people globally – an estimate predicted to rise up to approximately 700 million by 2045. With time, permanently high blood sugar levels caused either by autoimmune destruction of pancreatic beta cells (type 1 diabetes) or peripheral insulin resistance (type 2 diabetes) may lead to cardiovascular complications, kidney damage, among other causes of high morbidity and mortality among diabetic patients. SGLT2 inhibitors are the most recent class of antidiabetic drugs approved by regulatory authorities and have recently been associated with remarkable clinical outcomes in patients with diabetes and related comorbidities. This multidisciplinary review chapter covers the most recent and innovative synthetic approaches for the generation of gliflozin SGLT2 inhibitors, together with the newest results of clinical trials and real-world evidence studies, with special focus on the years of 2019 and 2020. Up-to-date data on glycemic control, cardioprotective and renoprotective effects of SGLT2 inhibitors are herein explored, as well as common adverse events experienced by patients in the course of their treatment, both in the context of type 1 and type 2 diabetes.

Editor(s)
J. Fischer, C. Klein, W.E. Childers

Date of Publication
2021-02-26

Institution
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA

Where published
Successful Drug Discovery

Publication Identifiers

Publisher
Wiley

Edition
1st
Volume
5

Number of pages
46
Starting page
111
Last page
157

Document Identifiers
DOI - https://doi.org/10.1002/9783527826872.ch4
URL - http://dx.doi.org/10.1002/9783527826872.ch4

Keywords
gliflozin-type SGLT2 inhibitors synthesis mechanism of action clinical benefits HbA1C levels cardiovascular protection renoprotection bodyweight reduction adverse effects type 1 diabetes


Export

APA
Ana M. Matos, Patrícia Calado, William Washburn, Amélia P. Rauter, (2021). Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events. Successful Drug Discovery, 111-157

IEEE
Ana M. Matos, Patrícia Calado, William Washburn, Amélia P. Rauter, "Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events" in Successful Drug Discovery, 2021, pp. 111-157

BIBTEX
@incollection{48729, author = {Ana M. Matos and Patrícia Calado and William Washburn and Amélia P. Rauter}, title = {Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events}, booktitle = {Successful Drug Discovery}, year = 2021, pages = {111-157}, address = {}, publisher = {Wiley} }